Waldenström Macroglobulinemia | Tumor

FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma

August 19th 2022

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

June 27th 2022

Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.

Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia

June 10th 2022

Brukinsa, which was approved in September 2021, resulted in better oucomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results

May 2nd 2022

The trial of CLR 131 (iopofosine) for relapsed/refractory Waldenstrom’s macroglobulinemia will continue, as the drug will be studied in an estimated 50 patients.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

HGTV Star Hilary Farr Shares Breast Cancer Journey, ‘Pistol Annies’ Singer Finishes Treatment and More

December 17th 2021

From the story of HGTV’s “Love it or List it” co-host Hilary Farr’s cancer journey to “Pistol Annies” singer Ashley Monroe ringing the bell after finishing cancer treatment, here’s what’s happening in the cancer landscape this week.

Several Factors May Impact a Waldenstrom’s Macroglobulinemia Treatment Decision

November 16th 2021

Without a huge difference in efficacy between many of the available treatments for Waldenstrom’s macroglobulinemia, one expert says patients and their clinicians should look to other factors when deciding which regimen is best.

FDA Approval of Brukinsa in Rare Lymphoma Offers a New Option, Though Will Not Replace Other Therapies

September 22nd 2021

The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.

Brukinsa Receives FDA Approval for Treatment of Waldenstrom’s Macroglobulinemia

September 1st 2021

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

Treating Waldenstrom’s Macroglobulinemia

December 17th 2020

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

December 6th 2020

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Drug Duo Granted Priority Review to Treat Waldenstrom Macroglobulinemia

June 25th 2018

The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.